Therapeutics News and Research

RSS

Unigene fourth quarter net income increases to $4.4 million

Unigene Laboratories, Inc., today announced financial results for the fourth quarter and full-year ended December 31, 2011.

9 Mar 2012

Celgene acquires Avila Therapeutics

Celgene Corporation today announced it has completed its acquisition of Avila Therapeutics. Celgene acquired Avila Therapeutics for $350 million in cash, plus up to $575 million contingent upon certain milestones related to AVL-292 and candidates from Avila's discovery program.

9 Mar 2012

Dr. Falk Pharma, Lipid Therapeutics enter license agreement for LT-02 to treat UC

Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.

8 Mar 2012

Surgical intervention can be life-restoring for people with intractable temporal lobe epilepsy

While the thought of any type of surgery can be disconcerting, the thought of brain surgery can be downright frightening. But for people with a particular form of epilepsy, surgical intervention can literally be life-restoring.

8 Mar 2012

MRF clinical trial to examine antigen-specific MS therapy

The Myelin Repair Foundation (MRF) announced today that its research might soon lead into a clinical proof-of-concept trial at the Department of Neuroimmunology and Multiple Sclerosis Research (nims), University Hospital Zürich, Switzerland, and the Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (inims) in Hamburg, Germany.

8 Mar 2012

Researchers identify key molecular player in mouse model of kidney disease

In findings that may lead to clinical trials of a promising new drug for kidney disease, researchers at Beth Israel Deaconess Medical Center (BIDMC) and their colleagues have identified a key molecular player and shown how a targeted experimental drug can reverse kidney damage in mouse models of diabetes, high blood pressure, genetic kidney disease, and other kidney injuries.

8 Mar 2012

March issue of NeuroPerspective reviews therapeutics for ADHD

NeuroPerspective, the independent, monthly review of the neurotherapeutics area, has released its March issue, which reviews the field of therapeutics for Attention Deficit Disorder.

8 Mar 2012

Researchers validate CatB protease as target for Alzheimer's

Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients.

8 Mar 2012

Celldex fourth quarter net loss increases to $12.7 million

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2011.

8 Mar 2012

Transgenomic fourth quarter total revenue increases 68% to $8.6M

Transgenomic, Inc. today reported financial results for the year ended December 31, 2011 and provided a business update.

7 Mar 2012

CTI fourth quarter net loss decreases to $17.9 million

Cell Therapeutics, Inc. today reported financial results and recent accomplishments for the fourth quarter and year ended December 31, 2011.

7 Mar 2012

Altogen launches new pancreas-targeted in vivo RNAi transfection system

Altogen Biosystems announced the launch of its new pancreas-targeted in vivo RNAi transfection system in the company's popular in vivo delivery product line for use in laboratories and research facilities for development of new medicines and testing in cells and animals.

7 Mar 2012

Pharmspective releases first knowledge management application: ClearView

Pharmspective, LLC today announced the release of its first knowledge management application - ClearView - specifically developed to analyze provisions in the health care reform law and their impact on key pharma customer decision makers who influence product adoption.

7 Mar 2012

Scripps scientists to develop new generation of broad spectrum anti-cancer therapeutics

A pair of Scripps Research Institute scientists, one a cancer biologist and the other a chemist, has been awarded $3.85 million from the National Institutes of Health (NIH) to develop a new generation of broad spectrum anti-cancer therapeutics, including breast cancer and lymphoma.

6 Mar 2012

Mount Sinai researchers argue different views of how to safely handle H5N1 flu viruses

In the controversy surrounding the newly developed strains of avian H5N1 flu viruses, scientists and policy makers are struggling with one question in particular: what level of biosafety is best for studying these potentially lethal strains of influenza? In a pair of commentaries, researchers from the Mount Sinai School of Medicine in New York and the University of Michigan argue their different views of how to safely handle H5N1 flu viruses.

6 Mar 2012

EntreMed plans to establish drug development office in China

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has initiated plans to establish an office in China to facilitate the Company's drug development and clinical trials in that country.

6 Mar 2012

Astex fourth quarter total revenues increase to $21.2 million

Astex Pharmaceuticals, Inc., today reported financial results for the fourth quarter and year ended December 31, 2011.

5 Mar 2012

MicroRNAs key to memory and learning process

Studying tiny bits of genetic material that control protein formation in the brain, Johns Hopkins scientists say they have new clues to how memories are made and how drugs might someday be used to stop disruptions in the process that lead to mental illness and brain wasting diseases.

5 Mar 2012

Certain microRNAs key to controlling actions of BDNF, linked to brain cell survival

5 Mar 2012

ACADIA, Allergan extend drug discovery collaboration

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc..

5 Mar 2012